

# Characterization of a Novel IQGAP1- ADRA2 axis as a Target of Norepinephrine in Lung Cancer

Tatiana B. De Souza<sup>1\*</sup>, Yusuf Barudi<sup>1</sup>, Mahasin A. Osman<sup>2</sup>,

<sup>1</sup>College of Medicine and Life Sciences, The University of Toledo, Toledo, OH  
43614

<sup>2</sup>Division of Hematology and Oncology, Department of Medicine, The University of  
Toledo, Toledo, OH 43614

\*Corresponding author: [tatiana.desouza@rockets.utoledo.edu](mailto:tatiana.desouza@rockets.utoledo.edu)

**Keywords:** IQGAP1, ADRA-2, Norepinephrine, Lung Cancer, Adrenergic Receptor  
 $\alpha$ -2a

Published: 14 December 2023

**Background:** Lung cancer is a leading cause of cancer death worldwide with few personalized treatment options. IQGAP1 is a signaling oncoprotein implicated in lung cancer, but its mechanism is poorly defined. In a yeast screen, the neurotransmitter/hormone norepinephrine (NE) was identified as an inhibitor of IQGAP1 in cell proliferation. As the GPCR Adrenergic Receptor  $\alpha$ -2a (ADRA-2a) is a known NE target, its link to IQGAP1 and NE utility in lung cancer therapy was investigated.

**Objectives:** Decipher the NE-IQGAP1-ADRA2 interplay in human lung cancer.

**Methods:** Western Blot was used to quantify ADRA-2a and IQGAP1 protein levels in several lung cancer cell lines. MTT assay was used to determine proliferation inhibition of lung cancer cell line and identify the NE IC50 dose. qRT-PCR was employed to measure NE effects on IQGAP1 and ADRA-2a mRNA levels in human cancer cell lines and WT and *iqgap1*<sup>-/-</sup> mouse embryonic fibroblasts (MEFs). Wound healing assays were used to measure the NE effects on cell migration capacity of lung cancer cells.

**Results:** ADRA-2 and IQGAP1 were differentially expressed in the different lung cancer cell lines. NE significantly reduced the ADRA-2 mRNA in normal but not lung cancer cells and insignificantly affected its level in WT MEFs. By contrast, in *iqgap1*<sup>-/-</sup> MEFs, NE appeared to increase ADRA-2 mRNA levels, suggesting that IQGAP1 influences ADRA-2a mRNA expression and that NE effects require IQGAP1. Interestingly, NE significantly reduced IQGAP1 mRNA in WT MEFs explaining the lack of effect on ADRA-2a. NE affected migration differently among lung cancer cell lines, suggesting a more individualized approach to developing future NE-based therapy.

**Conclusion:** IQGAP1 appears to negatively regulates ADRA-2a expression and can serve as an NE target in lung cancer.